Navigation Links
Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
Date:3/6/2013

SAN DIEGO, March 6, 2013 /PRNewswire/ -- Cylene Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license. 

TetraGene is developing small molecule drugs aimed at highly validated cancer-causing genes, by directly targeting G-quadruplex structures in genomic DNA. TetraGene has the option to acquire worldwide rights to the technologies licensed from Cylene, which include the Phase II compound Quarfloxin and several registered patents. Quarfloxin has been demonstrated to be safe and well-tolerated in Phase I clinical trials.

"This agreement is a clear win for both organizations," stated William G. Rice , PhD, President and CEO of Cylene Pharmaceuticals. "TetraGene is well placed to advance Quarfloxin through the clinic and to capture exclusive worldwide rights to the quadruplex-targeting technologies.  Cylene will receive standard industry payments as the quadruplex program progresses and we will continue to focus our in-house development efforts on CX-5461, Cylene's clinical stage Pol I inhibitor that activates the p53 tumor suppressor selectively in cancer cells and not normal cells."

"The agreement between TetraGene and Cylene immediately provides us with access to a clinical stage drug," commented Laurence H. Hurley , PhD, CSO of TetraGene and a pioneer of G-quadruplex targeted therapeutics. "The validity of drug targeting G-quadruplex DNA and modulating expression of cancer genes has dramatically increased in the last few years and our team is uniquely positioned to take advantage of these new insights."

About Cylene Pharmaceuticals
Cylene Pharmaceuticals is a clinical-stage private company developing small molecule drugs against newly validated targets in essential cancer pathways.  The Company's Pol I program provides a non-genotoxic mechanism for activating p53 to kill cancer cells.  Cylene's leadership in exploiting CK2 pathways enables rational drug combinations for improved treatment outcomes against many cancer indications.  Cylene's unique approaches deliver innovative cancer agents that can enable pharmaceutical companies to expand their portfolios and extend the efficacy, lifecycle and reach of current cancer therapeutics. For more information on Cylene and its programs, please visit www.cylenepharma.com.

About TetraGene
TetraGene leverages a novel platform technology to develop cancer drugs that target well-validated cancer-causing oncogenes previously considered as undruggable by the pharmaceutical industry. This technology exploits a gene regulatory mechanism where the expression of a gene is controlled by folded DNA structures (called G-quadruplex DNA). By targeting gene transcription, TetraGene has carved out a niche where its technology platform can be directly applied to inhibit these undruggable cancer targets.  For more information about TetraGene please visit www.tetragene.com.


'/>"/>
SOURCE Cylene Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
2. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
3. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
4. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
5. TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
6. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
7. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
8. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
9. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
10. AVANIR Pharmaceuticals To paticipate in two conferences in March
11. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Eli Lilly and Company (NYSE: LLY ... in its U.S. operations in 2017. The company,s ... research laboratories, manufacturing sites, and general and administrative ... for Lilly products, as well as its robust ... pain, diabetes and other unmet medical needs.  ...
(Date:3/24/2017)... Tenn. , March 23, 2017  Provectus ... or the "Company"), a clinical-stage oncology and dermatology ... announced Definitive Financing Commitment Term Sheet (the "Definitive ... a group of the Company,s stockholders, who are ... Group" in a Form 8-K filed with the ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Analysis & Trends - Industry Forecast to 2025" report to ... ... of around 6.9% over the next decade to reach approximately $3.5 ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter ... the same time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to ... premier prehospital trauma education developed in cooperation with the American College of Surgeons ...
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation ... the opening of a Greenville, South Carolina location. The lab has set ... Greenville. , “We’ve been working with South Carolina clients for years from our office ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Texas ... which can be found at 9618 Huebner Road. The clinic is the group’s 7th ... Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly ... Delgado, June 9--24, 2017. This sacred and spiritual journey during the Summer ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
Breaking Medicine News(10 mins):